Richard Giltner Biography and Net Worth

Director of United Therapeutics

From 2009 until his retirement in 2010, Mr. Giltner was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale.

From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010.

Mr. Giltner received his bachelor's degree from Northwestern University.

Mr. Giltner brings to our Board decades of experience in the financial sector, including international financial markets, financial derivatives, alternative investments, and asset management. As our business continues to grow and expand, our Board benefits from Mr. Giltner’s global business and financial experience and his perspective as an institutional investor, as well as his leadership experience in international finance from his service in various management roles at Société Générale. Our Board has determined that Mr. Giltner is an audit committee financial expert as defined under the rules and regulations of the SEC and meets the financial sophistication requirements of Nasdaq’s listing standards for Audit Committee members.

What is Richard Giltner's net worth?: The estimated net worth of Richard Giltner is at least $9.38 million as of June 24th, 2025. Mr. Giltner owns 19,384 shares of United Therapeutics stock worth more than $9,383,794 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Giltner may own. Learn More about Richard Giltner's net worth.
How do I contact Richard Giltner?: The corporate mailing address for Mr. Giltner and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Richard Giltner's contact information.
Has Richard Giltner been buying or selling shares of United Therapeutics?: Richard Giltner has not been actively trading shares of United Therapeutics during the past quarter. Most recently, Richard Giltner sold 3,036 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a transaction totalling $879,225.60. Following the completion of the sale, the director now directly owns 19,384 shares of the company's stock, valued at $5,613,606.40. Learn More on Richard Giltner's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Richard Giltner (Director), Paul Mahon (EVP), Jan Malcolm (Director), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), Louis Sullivan (Director), and Tommy Thompson (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 92 times. They sold a total of 892,280 shares worth more than $364,227,874.83. The most recent insider tranaction occured on December, 1st when CFO James Edgemond sold 21,000 shares worth more than $10,079,790.00. Insiders at United Therapeutics own 10.3% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 12/1/2025.

Richard Giltner Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2025	Sell	3,036	$289.60	$879,225.60	19,384
4/20/2020	Sell	5,000	$107.00	$535,000.00	8,750
4/14/2020	Sell	5,000	$99.00	$495,000.00	8,750
3/26/2020	Sell	5,000	$91.75	$458,750.00	8,750
6/20/2019	Sell	5,000	$79.05	$395,250.00	5,000
8/16/2018	Sell	3,240	$129.38	$419,191.20
7/5/2017	Sell	3,490	$131.12	$457,608.80
12/6/2016	Sell	5,000	$133.37	$666,850.00	5,000
11/3/2015	Sell	7,500	$153.22	$1,149,150.00
9/25/2014	Sell	20,000	$134.94	$2,698,800.00
9/10/2014	Sell	20,000	$119.95	$2,399,000.00

Richard Giltner Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $484.10

$477.56

$486.46

50 Day Range

MA: $451.78

$415.34

$488.43

2 Week Range

Now: $484.10

$266.98

$492.62

Volume

630,738 shs

Average Volume

396,916 shs

Market Capitalization

$20.85 billion

P/E Ratio

18.34

Dividend Yield

N/A

Beta

0.86